MDMApopularly referred to as ecstasy is known to promote high empathyfeelings in users and is categorized as a Schedule 1 drug. Schedule 1drugs are a category that is reserved for compounds that have norecognized medical use as well as a high abuse probability. Despitethis established fact, new information has emerged pointing to theneed for further experiments on MDMA. In an article that waspublished in July in Cell and available on the Science Daily website(link available below), two researchers were reported to be callingfor a rigorous scientific investigation of the effects of MDMA toascertain precisely the way the drug works (Cell Press, 2016). Theresearchers suggest that the data from the exploration can be appliedto advance therapeutic compounds. A psychiatrist, as well as aneuroscientist at the Stanford University, called Robert Malenkaargues that the scientists need to understand the molecular targetsof MDMA and the pharmaceutical as well as biotech industries payattention. The outcome will be the development of drugs that canmaintain the probable therapeutic effects for conditions, such asPTSD and autism. This article is insightful and offers a foundationupon which the development of other drugs can be based. It has beenestablished that presently researchers do not understand exactly theway MDMA works when used, the areas of the brain that it targets, oreven the molecular pathways affected. Therefore, with the scarceinformation available on the pharmacology of MDMA, an elaborateexperiment on the drug will create more avenues for determining thebenefits as well as the side effects (Peroutka, 2012). Despite thereason that every researcher is conversant with the regulated statusof MDMA, this should not discourage them from studying its mechanismof action as well as effects.
CellPress. (2016).Whyscientists are calling for experiments on ecstasy.Retrieved fromhttps://www.sciencedaily.com/releases/2016/07/160714134748.htmPeroutka,S. (2012).Ecstasy: The clinical, pharmacological and neurotoxicological effectsof the drug MDMA.Boston: Springer Science & Business Media.